Only One in Four AAV Immunosuppression Starts Receive PJP Prophylaxis
This Medicare claims analysis quantifies how sex, region, and county-level poverty relate to guideline-concordant Pneumocystis prophylaxis in antineutrophil cytoplasmic antibody-associated vasculitis, a gap pharmacists are positioned to close.
📅 Journal publication: Dec 2026(online Sep 17, 2026)·Last updated: Nov 10, 2026
Low PJP prophylaxis in AAV patients raises concern for infections.
Infections are a leading cause of complications in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and prophylaxis is underutilized. Prophylaxis was only used in 26% of cases, with lower use in females and those from high poverty areas. The study highlights disparities in prophylaxis utilization, but its claims-based data might suffer from misclassification and lacks causal inference. Address gaps in PJP prophylaxis to enhance outcomes for AAV patients.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Citation:Cao B, Hickson RP, Zhao X, et al. Association of Demographic, Economic, and Geographic Factors With Guideline-Concordant Infection Prophylaxis in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Kidney medicine. 2026;8(12):101538. doi:10.1016/j.xkme.2026.101538